BPC-157 for Post-Surgery Recovery: Protocol, Dosing, and What to Expect
Evidence strength: strong
What this protocol is for
Post-surgery is one of the cleanest cases for BPC-157. The mechanism maps directly to what the body is already doing in the wound bed: angiogenesis to feed the repair, fibroblast migration to lay down the matrix, growth-factor receptor upregulation to amplify local signaling. The peptide does not replace the surgical work. It accelerates the back end of the recovery curve.
The right window matters. Most protocols start 1–2 weeks post-op once acute inflammation has settled and the surgical team has cleared tissue-support intervention. The immediate post-op window has its own biological choreography. Adding peptides into that window without clearance is not tactical, it is risk. The mid-recovery window, after the acute inflammatory phase, is where BPC-157 earns its place.
Used by many in the recovery / biohacking space for tendon repairs, ACL reconstructions, rotator cuff procedures, and abdominal surgeries. Research shows the mechanistic case is strong. Anecdotally, users report faster scar healing, faster return to baseline range of motion, and earlier physio progress. Expect to hit the surgical team's milestones 1–3 weeks ahead of schedule. Not faster than that. The return-to-play timeline gets pulled in by a fortnight, not a season.
This protocol is a tactical layer on top of the surgical and physio work, not a substitute for either. Confirm dose and timing with the operating surgical team before starting.
Dose for post-surgery recovery
250 to 500 mcg per day subcutaneous, starting 1–2 weeks post-op with surgical clearance. Abdominal subcutaneous is the systemic default. Split AM and PM. Some protocols combine systemic with carefully placed subcutaneous injections near the surgical site when the soft tissue is accessible. Confirm dose and timing with the operating surgical team before starting. Some surgeons are open to peptide support, others are not. Both positions are defensible.
Cycle length
4–8 weeks continuous, beginning 1–2 weeks post-op. Simple soft-tissue repairs at the shorter end. Complex reconstructions and tendon-to-bone procedures at the longer end. Reassess with the surgical team before extending past 8 weeks.
Stack pairings
Commonly stacked with TB-500.
Expected timeline
Week 1–2 post-op (typical start): inflammation drops below the expected post-surgical baseline. Pain trajectory improves faster than the surgical team predicted. Week 2–4: faster wound healing, scar tissue lays down with better organisation, lighter range-of-motion work feels comfortable sooner. Week 4–8: physio milestones land 1–3 weeks earlier than the original timeline. Most users hit functional return-to-activity ahead of schedule.
Common mistakes
- Starting BPC-157 immediately post-op without surgical clearance. The acute inflammatory phase has its own healing signal the surgeon is tracking. Unsanctioned intervention is not a tactical move there.
- Stopping the protocol the moment you get cleared for full activity. The most important gains often come from the final 2–3 weeks of tissue remodeling.
- Chronic NSAID or steroid overlap without clinical input. Interactions are not fully characterised and the surgical team usually has a specific anti-inflammatory plan for the recovery window.
- Skipping physiotherapy load progression because recovery feels easy. BPC-157 reduces pain ahead of structural readiness. That gap is where re-injury lives.